The first three days seem to represent a relatively safe period during which surgery for macula-off retinal detachment may be postponed without compromising the patient's visual prognosis.

Photodynamic therapy combined with injection of intravitreal bevacizumab tends to be more effective compared to PDT monotherapy by reducing the post-PDT increase of vascular growth and inflammatory factors. Our short-term results are very promising. Further studies are necessary to show the long-term effect of PDT and anti-VEGF combination therapy.

Purpose To discuss the influence of AMD on critical flicker fusion frequency (CFF) Methods CFF was measured centrally for red, green and blue signal and in 10° excentricity with a red signal. 33 patients with non exsudative AMD and a visual acuity (VA) of 20/100‐20/20, 12 patients with exsudative AMD (VA: 20/100‐20/25) and 45 age‐matched healthy eyes (VA: 20/32‐20/20) were included. Results CFF decreased in eyes with non exsudative AMD (red 1,6Hz p=0,01, green 1,6 Hz p=0,04, blue 2,1 Hz p=0,01). The difference between central and peripher CFF increased (red‐red 10°, 1,0 Hz p=0,01). Differences between different colours were low and reached no significance. In eyes with exsudative AMD CFF showed lower values (red 2.2 Hz p=0.02, green 3.3 Hz p=0.001, blue 2,9 Hz p=0.02, but in spite of increased difference between central and peripher CFF had no statistical significance. (red‐red 10° , 1,3 Hz p=0,25). Eyes with exsudative AMD showed a 1.0 Hz (p=0.02) higher difference between CFF with a red and a green signal than healthy eyes. Sub‐group analysis of patients with non exsudative AMD and visual acuity better than 20/32 (n=20) and healthy eyes showed no difference. Patients with non exsudative (n=13) and eyes with exsudative AMD (n=7) and VA between 20/200 and 20/40 reached equal CFF values. Conclusion CFF was decreased in non exsudative and exsudative AMD. The difference between central and peripher CFF increased in exsudative and nonexsudative AMD. Exsudative AMD has a stronger impact on a green than on a red signal. CFF is not able to distinguish between groups of equal visual acuity and therefore not applicable as a diagnostic test.

Intravitreal therapy with bevacizumab was safe and well tolerated. It is a therapeutic option in treating occult choroidal neovascularisations and minimal classic CNV. Six months after intravitreal administration of bevacizumab mean visual acuity was stabilised. Retinal thickness and leakage were more reduced after 1 month than after 3 and 6 months. According to our results, a monthly injection schedule could give more favourable results.